A newly approved immunotherapy can help adults with a difficult-to-treat form of leukemia, clinical trial results show ...

Adoptive cell transfer with chimeric antigen receptor (CAR)-expressing T cells can induce remarkable complete responses in ...

11月27日，中南大学湘雅二医院血液内科彭宏凌教授团队在国际权威期刊Journal of Clinical Investigation（IF=19.4）发表了题为《IL-2-inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy against tumor cells》的原创性研究论文 ...

Preclinical studies showed that the addition of IL-15 could improve the performance of CAR T cell-based immunotherapies.

The study reveals IL-15's role in enhancing GPC3 CAR T cell therapy, improving tumor targeting and T cell survival in ...

Matias Sanchez, MD, assistant professor in the Department of Medicine at the University of Illinois Chicago, discussed recent advancements in multiple myeloma treatment, including the potential of ...

Immunotherapies have shaped the cancer research space over the past decade, proving effective for the treatment of some ...

A novel CAR T-cell therapy has benefitted patients with relapsed acute lymphoblastic leukemia, showing high response rates in ...

Roche will acquire Poseida Therapeutics, building on a partnership for CAR T-cell therapies in development for MS and other ...

After posting "oustanding" pivotal trial data, Orthocell will apply for US FDA approval of its Remplir nerve-repair product.

红网时刻新闻11月30日讯（通讯员 李姮 张清洋）11月27日，中南大学湘雅二医院血液内科彭宏凌教授团队在国际权威期刊Journal of Clinical Investigation（IF=19.4）发表了题为《IL-2-inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy aga ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it ...